Systematic IUPAC name
S,8 R,9 S,10 R,13 S,14 S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[ a]phenanthren-17-one
Androstenolone; Prasterone; Androst-5-en-3β-ol-17-one; 5,6-Didehydroepiandrosterone;
ECHA InfoCard 100.000.160
C 19 H 28 O 2
QA14AA07 ( ) WHO G03EA03 ( ) (combination with WHO estrogen)
By mouth, vaginal ( insert), intramuscular injection (as prasterone enanthate), injection (as prasterone sodium sulfate)
DHEA: 25 minutes  DHEA-S: 11 hours
Except where otherwise noted, data are given for materials in their
(at 25 °C [77 °F], 100 kPa).
( verify what is ?)
Dehydroepiandrosterone ( DHEA), also known as androstenolone, is an endogenous steroid hormone precursor. It is one of the most abundant circulating  steroids in humans. DHEA is produced in the  adrenal glands, the  gonads, and the brain. It functions as a  metabolic intermediate in the biosynthesis of the androgen and estrogen sex steroids both in the gonads and in various other tissues.   However, DHEA also has a variety of potential biological effects in its own right, binding to an array of  nuclear and cell surface receptors, and acting as a  neurosteroid and modulator of neurotrophic factor receptors.
In the United States, DHEA is sold as an
over-the-counter supplement, and medication called prasterone.
As an androgen
DHEA and other adrenal androgens such as
androstenedione, although relatively weak androgens, are responsible for the androgenic effects of adrenarche, such as early pubic and axillary hair growth, adult-type body odor, increased oiliness of hair and skin, and mild acne.   DHEA is potentiated locally via conversion into  testosterone and dihydrotestosterone (DHT) in the skin and hair follicles. Women with  complete androgen insensitivity syndrome (CAIS), who have a non-functional androgen receptor (AR) and are immune to the androgenic effects of DHEA and other androgens, have absent or only sparse/scanty pubic and axillary hair and body hair in general, demonstrating the role of DHEA and other androgens in body hair development at both adrenarche and pubarche.   
As an estrogen
DHEA is a weak
estrogen.   In addition, it is transformed into potent estrogens such as  estradiol in certain tissues such as the vagina, and thereby produces estrogenic effects in such tissues.
As a neurosteroid
neurosteroid and neurotrophin, DHEA has important effects in the central nervous system.  
Although it functions as an endogenous
precursor to more potent androgens such as testosterone and DHT, DHEA has been found to possess some degree of androgenic activity in its own right, acting as a low affinity (K i = 1 μM), weak partial agonist of the androgen receptor (AR). However, its intrinsic activity at the receptor is quite weak, and on account of that, due to competition for binding with full agonists like testosterone, it can actually behave more like an antagonist depending on circulating testosterone and dihydrotestosterone (DHT) levels, and hence, like an antiandrogen. However, its affinity for the receptor is very low, and for that reason, is unlikely to be of much significance under normal circumstances. 
In addition to its affinity for the androgen receptor, DHEA has also been found to bind to (and activate) the
ERα and ERβ estrogen receptors with K i values of 1.1 μM and 0.5 μM, respectively, and EC values of >1 μM and 200 nM, respectively. Though it was found to be a partial agonist of the ERα with a maximal efficacy of 30–70%, the concentrations required for this degree of activation make it unlikely that the activity of DHEA at this receptor is physiologically meaningful. Remarkably however, DHEA acts as a full agonist of the ERβ with a maximal response similar to or actually slightly greater than that of 50 estradiol, and its levels in circulation and local tissues in the human body are high enough to activate the receptor to the same degree as that seen with circulating estradiol levels at somewhat higher than their maximal, non- ovulatory concentrations; indeed, when combined with estradiol with both at levels equivalent to those of their physiological concentrations, overall activation of the ERβ was doubled. 
Other nuclear receptors
DHEA does not bind to or activate the
progesterone, glucocorticoid, or mineralocorticoid receptors.  Other  nuclear receptor targets of DHEA besides the androgen and estrogen receptors include the PPARα, PXR, and CAR. However, whereas DHEA is a  ligand of the PPARα and PXR in rodents, it is not in humans. In addition to direct interactions, DHEA is thought to regulate a handful of other  proteins via indirect, genomic mechanisms, including the enzymes CYP2C11 and 11β-HSD1 – the latter of which is essential for the biosynthesis of the glucocorticoids such as cortisol and has been suggested to be involved in the antiglucocorticoid effects of DHEA – and the carrier protein IGFBP1. 
DHEA has been found to directly act on several
neurotransmitter receptors, including acting as a positive allosteric modulator of the NMDA receptor, as a negative allosteric modulator of the GABA, and as an A receptor agonist of the σ. 1 receptor 
In 2011, the surprising discovery was made that DHEA, as well as its sulfate ester,
DHEA-S, directly bind to and activate TrkA and p75, receptors of NTR neurotrophins like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), with high affinity.  DHEA was subsequently also found to bind to  TrkB and TrkC with high affinity, though it only activated TrkC not TrkB.  DHEA and DHEA-S bound to these receptors with affinities in the low  nanomolar range (around 5 nM), which were nonetheless approximately two orders of magnitude lower relative to highly potent polypeptide neurotrophins like NGF (0.01–0.1 nM).   In any case, DHEA and DHEA-S both circulate at requisite concentrations to activate these receptors and were thus identified as important endogenous  neurotrophic factors.  They have since been labeled "steroidal  microneurotrophins", due to their small-molecule and steroidal nature relative to their polypeptide neurotrophin counterparts. Subsequent research has suggested that DHEA and/or DHEA-S may in fact be phylogenetically ancient "ancestral" ligands of the neurotrophin receptors from early on in the  evolution of the nervous system.  The findings that DHEA binds to and potently activates  neurotrophin receptors may explain the positive association between decreased circulating DHEA levels with age and age-related neurodegenerative diseases. 
Microtubule-associated protein 2
pregnenolone, its synthetic derivative 3β-methoxypregnenolone (MAP-4343), and progesterone, DHEA has been found to bind to microtubule-associated protein 2 (MAP2), specifically the MAP2C subtype (K d = 27 μM). However, it is unclear whether DHEA increases binding of MAP2 to  tubulin like pregnenolone.
DHEA is an
uncompetitive inhibitor of (K G6PDH i = 17 μM; IC = 18.7 μM), and is able to lower 50 levels and reduce NADPH-dependent NADPH free radical production.  It is thought that this action may possibly be responsible for much of the  antiinflammatory, antihyperplastic, chemopreventative, antihyperlipidemic, antidiabetic, and antiobesic, as well as certain immunomodulating activities of DHEA (with some experimental evidence to support this notion available).    However, it has also been said that inhibition of G6PDH activity by DHEA  has not been observed and that the concentrations required for DHEA to inhibit G6PDH in vivo are very high, thus making the possible contribution of G6PDH inhibition to the effects of DHEA uncertain. in vitro
DHEA supplements have been promoted for their claimed cancer prevention properties, but there is no scientific evidence to support these claims.
DHEA has been found to competitively inhibit
DHEA is produced in the
zona reticularis of the adrenal cortex under the control of adrenocorticotropic hormone (ACTH) and by the gonads under the control of gonadotropin-releasing hormone (GnRH).  It is also produced in the  brain. DHEA is synthesized from  cholesterol via the enzymes cholesterol side-chain cleavage enzyme (CYP11A1; P450scc) and 17α-hydroxylase/17,20-lyase (CYP17A1), with pregnenolone and 17α-hydroxypregnenolone as intermediates. It is derived mostly from the  adrenal cortex, with only about 10% being secreted from the gonads.   Approximately 50 to 70% of circulating DHEA originates from desulfation of DHEA-S in peripheral tissues.  DHEA-S itself originates almost exclusively from the adrenal cortex, with 95 to 100% being secreted from the adrenal cortex in women.  
Increasing endogenous production
exercise is known to increase DHEA production in the body.   Calorie restriction has also been shown to increase DHEA in primates. Some theorize that the increase in endogenous DHEA brought about by calorie restriction is partially responsible for the longer life expectancy known to be associated with calorie restriction. 
 Catalpol and a combination of acetyl-carnitine and propionyl-carnitine on 1:1 ratio also improves endogenous DHEA production and release due to direct cholinergic stimulation of CRH release and an increase of IGF-1 expression respectively.
circulation, DHEA is mainly bound to albumin, with a small amount bound to sex hormone-binding globulin (SHBG).  The small remainder of DHEA not associated with albumin or SHBG is unbound and free in the circulation. 
DHEA easily crosses the
blood–brain barrier into the central nervous system.
DHEA is transformed into DHEA-S by
sulfation at the C3β position via the sulfotransferase enzymes SULT2A1 and to a lesser extent SULT1E1.   This occurs naturally in the adrenal cortex and during  first-pass metabolism in the liver and intestines when exogenous DHEA is administered orally. Levels of DHEA-S in circulation are approximately 250 to 300 times those of DHEA.  DHEA-S in turn can be converted back into DHEA in peripheral tissues via  steroid sulfatase (STS). 
terminal half-life of DHEA is short at only 15 to 30 minutes. In contrast, the terminal half-life of DHEA-S is far longer, at 7 to 10 hours.  As DHEA-S can be converted back into DHEA, it serves as a circulating reservoir for DHEA, thereby extending the  duration of DHEA. 
Metabolites of DHEA include DHEA-S, 7α-hydroxy-DHEA, 7β-hydroxy-DHEA, 7-keto-DHEA, 7α-hydroxyepiandrosterone, and 7β-hydroxyepiandrosterone, as well as androstenediol and androstenedione.
pregnancy, DHEA-S is metabolized into the sulfates of 16α-hydroxy-DHEA and 15α-hydroxy-DHEA in the fetal liver as intermediates in the production of the estrogens estriol and estetrol, respectively.
puberty, DHEA and DHEA-S levels elevate upon differentiation of the zona reticularis of the adrenal cortex. Peak levels of DHEA and DHEA-S are observed around age 20, which is followed by an age-dependent decline throughout life eventually back to prepubertal concentrations.  Plasma levels of DHEA in adult men are 10 to 25 nM, in premenopausal women are 5 to 30 nM, and in postmenopausal women are 2 to 20 nM.  Conversely, DHEA-S levels are an order of magnitude higher at 1–10 μM.  Levels of DHEA and DHEA-S decline to the lower nanomolar and micromolar ranges in men and women aged 60 to 80 years. 
DHEA levels are as follows:
Adult men: 180–1250 ng/dL
Adult women: 130–980 ng/dL
Pregnant women: 135–810 ng/dL
Prepubertal children (<1 year): 26–585 ng/dL
Prepubertal children (1–5 years): 9–68 ng/dL
Prepubertal children (6–12 years): 11–186 ng/dL
Adolescent boys (Tanner II–III): 25–300 ng/dL
Adolescent girls (Tanner II–III): 69–605 ng/dL
Adolescent boys (Tanner IV–V): 100–400 ng/dL
Adolescent girls (Tanner IV–V): 165–690 ng/dL
As almost all DHEA is derived from the adrenal glands, blood measurements of DHEA-S/DHEA are useful to detect excess adrenal activity as seen in adrenal cancer or hyperplasia, including certain forms of
congenital adrenal hyperplasia. Women with polycystic ovary syndrome tend to have elevated levels of DHEA-S.
DHEA, also known as androst-5-en-3β-ol-17-one, is a
naturally occurring androstane steroid and a 17-ketosteroid. It is closely related structurally to  androstenediol (androst-5-ene-3β,17β-diol), androstenedione (androst-4-ene-3,17-dione), and testosterone (androst-4-en-17β-ol-3-one). DHEA is the 5-  dehydro analogue of epiandrosterone (5α-androstan-3β-ol-17-one) and is also known as 5-dehydroepiandrosterone or as δ 5-epiandrosterone.
The term "dehydroepiandrosterone" is ambiguous chemically because it does not include the specific positions within epiandrosterone at which hydrogen atoms are missing. DHEA itself is 5,6-didehydroepiandrosterone or 5-dehydroepiandrosterone. A number of naturally occurring isomers also exist and may have similar activities. Some isomers of DHEA are
1-dehydroepiandrosterone (1-androsterone) and 4-dehydroepiandrosterone. These isomers are also technically "DHEA", since they are dehydroepiandrosterones in which hydrogens are removed from the  epiandrosterone skeleton.
Dehydroandrosterone (DHA) is the 3α- epimer of DHEA and is also an endogenous androgen.
DHEA was first isolated from human
urine in 1934 by Adolf Butenandt and Kurt Tscherning.
Devillers J (27 April 2009). . CRC Press. pp. 339–. Endocrine Disruption Modeling ISBN . 978-1-4200-7636-3
^ a b
Cupp MJ, Tracy TS (10 December 2002). . Springer Science & Business Media. pp. 135–. Dietary Supplements: Toxicology and Clinical Pharmacology ISBN . 978-1-59259-303-3
^ a b
Oddens BJ, Vermeulen A (15 November 1996). . CRC Press. pp. 5–. Androgens and the Aging Male ISBN . 978-1-85070-763-9
^ a b c d e
Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G, Labrie C (November 2005). "Is dehydroepiandrosterone a hormone?". J. Endocrinol. 187 (2): 169–96. doi: . 10.1677/joe.1.06264 PMID 16293766.
^ William F Ganong MD, 'Review of Medical Physiology', 22nd Ed, McGraw Hill, 2005, p. 362.
The Merck Index, 13th Edition, 7798
Schulman RA, Dean C (2007). Solve It With Supplements. New York City: Rodale, Inc. p. 100. ISBN . 978-1-57954-942-8 DHEA (Dehydroepiandrosterone) is a common hormone produced in the adrenal glands, the gonads, and the brain.
^ a b
Mo Q, Lu SF, Simon NG (April 2006). "Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity". The Journal of Steroid Biochemistry and Molecular Biology. 99 (1): 50–8. doi: 10.1016/j.jsbmb.2005.11.011. PMID 16524719.
Scott T (1996). . Walter de Gruyter. p. Concise Encyclopedia Biology 49. ISBN 978-3-11-010661-9 . Retrieved . 25 May 2012
^ a b c
Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK (2006). "The biological actions of dehydroepiandrosterone involves multiple receptors". Drug Metabolism Reviews. 38 (1–2): 89–116. doi: 10.1080/03602530600569877. PMC . 2423429 PMID 16684650.
Friess E, Schiffelholz T, Steckler T, Steiger A (December 2000). "Dehydroepiandrosterone--a neurosteroid". European Journal of Clinical Investigation. 30 Suppl 3: 46–50. doi: 10.1046/j.1365-2362.2000.0300s3046.x. PMID 11281367.
Pescovitz OH, Eugster EA (2004). . Lippincott Williams & Wilkins. pp. 362–. Pediatric Endocrinology: Mechanisms, Manifestations, and Management ISBN . 978-0-7817-4059-3
Fima Lifshitz (26 December 2006). . CRC Press. pp. 289–. Pediatric Endocrinology: Growth, Adrenal, Sexual, Thyroid, Calcium, and Fluid Balance Disorders ISBN . 978-1-4200-4272-6
Salhan S (1 August 2011). . JP Medical Ltd. pp. 94–. Textbook of Gynecology ISBN . 978-93-5025-369-4
Lavery JP, Sanfilippo JS (6 December 2012). . Springer Science & Business Media. pp. 45–. Pediatric and Adolescent Obstetrics and Gynecology ISBN . 978-1-4612-5064-7
Nussbaum RL, McInnes RR, Willard HF (28 April 2015). . Elsevier Health Sciences. pp. 102–. Thompson & Thompson Genetics in Medicine ISBN . 978-0-323-39206-8
Setchell ME, Hudson CN (4 April 2013). . Elsevier Health Sciences. pp. 129–. Shaw's Textbook of Operative Gynaecology ISBN . 978-81-312-3481-5
Bissonnette B, Dalens B (20 July 2006). . McGraw Hill Professional. p. 184. Syndromes: Rapid Recognition and Perioperative Implications ISBN . 978-0-07-135455-4
^ a b c d e
Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP, Reszka AA (November 2005). "Direct agonist/antagonist functions of dehydroepiandrosterone". Endocrinology. 146 (11): 4568–76. doi: . 10.1210/en.2005-0368 PMID 15994348.
^ a b c
Weizman A (1 February 2008). . Springer Science & Business Media. pp. 229–. Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment ISBN . 978-1-4020-6854-6
Gravanis AG, Mellon SH (24 June 2011). . John Wiley & Sons. pp. 349–. Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis ISBN . 978-3-527-63397-5
. Elsevier. 3 December 2010. pp. 127–. Sex difference in the human brain, their underpinnings and implications ISBN . 978-0-444-53631-0
Gao W, Bohl CE, Dalton JT (September 2005). "Chemistry and structural biology of androgen receptor". Chemical Reviews. 105 (9): 3352–70. doi: 10.1021/cr020456u. PMC . 2096617 PMID 16159155.
Lindschau C, Kirsch T, Klinge U, Kolkhof P, Peters I, Fiebeler A (September 2011). "Dehydroepiandrosterone-induced phosphorylation and translocation of FoxO1 depend on the mineralocorticoid receptor". Hypertension. 58 (3): 471–8. doi: . 10.1161/HYPERTENSIONAHA.111.171280 PMID 21747041.
^ a b c d e f g h i j k l m n o
Prough RA, Clark BJ, Klinge CM (April 2016). "Novel mechanisms for DHEA action". Journal of Molecular Endocrinology. 56 (3): R139–55. doi: . 10.1530/JME-16-0013 PMID 26908835.
Watson RR (22 July 2011). . CRC Press. pp. 208–. DHEA in Human Health and Aging ISBN . 978-1-4398-3884-6
Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W (February 1994). "Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA)". Molecular and Cellular Biochemistry. 131 (2): 99–104. doi: 10.1007/BF00925945. PMID 8035785.
^ a b
King SR (9 November 2012). . Springer Science & Business Media. pp. 15–16. Neurosteroids and the Nervous System ISBN . 978-1-4614-5559-2
^ a b c d
Lazaridis I, Charalampopoulos I, Alexaki VI, Avlonitis N, Pediaditakis I, Efstathopoulos P, Calogeropoulou T, Castanas E, Gravanis A (April 2011). "Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis". PLoS Biology. 9 (4): e1001051. doi: 10.1371/journal.pbio.1001051. PMC . 3082517 PMID 21541365.
^ a b c
Pediaditakis I, Iliopoulos I, Theologidis I, Delivanoglou N, Margioris AN, Charalampopoulos I, Gravanis A (January 2015). "Dehydroepiandrosterone: an ancestral ligand of neurotrophin receptors". Endocrinology. 156 (1): 16–23. doi: . 10.1210/en.2014-1596 PMID 25330101.
Gravanis A, Calogeropoulou T, Panoutsakopoulou V, Thermos K, Neophytou C, Charalampopoulos I (October 2012). "Neurosteroids and microneurotrophins signal through NGF receptors to induce prosurvival signaling in neuronal cells". Science Signaling. 5 (246): pt8. doi: 10.1126/scisignal.2003387. PMID 23074265.
^ a b
Schwartz AG, Pashko LL (April 2004). "Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity". Ageing Research Reviews. 3 (2): 171–87. doi: 10.1016/j.arr.2003.05.001. PMID 15177053.
^ a b c
Ciolino HP, MacDonald CJ, Yeh GC (July 2002). "Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one". Cancer Research. 62 (13): 3685–90. PMID 12097275.
McCormick DL, Johnson WD, Kozub NM, Rao KV, Lubet RA, Steele VE, Bosland MC (February 2007). "Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone". Carcinogenesis. 28 (2): 398–403. doi: . 10.1093/carcin/bgl141 PMID 16952912.
Auci D, Kaler L, Subramanian S, Huang Y, Frincke J, Reading C, Offner H (September 2007). "A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells". Annals of the New York Academy of Sciences. 1110: 630–40. doi: 10.1196/annals.1423.066. PMID 17911478.
Russell J, Rovere A, eds. (2009). . "DHEA" American Cancer Society Complete Guide to Complementary and Alternative Cancer Therapies (2nd ed.). American Cancer Society. pp. 729-733. ISBN . 9780944235713
Häggström, Mikael; Richfield, David (2014). "Diagram of the pathways of human steroidogenesis". WikiJournal of Medicine. 1 (1). doi: . 10.15347/wjm/2014.005 ISSN 2002-4436.
^ a b
Erkkola R (2006). . Elsevier. pp. 5–. The Menopause ISBN . 978-0-444-51830-9
Kleine B, Rossmanith WG (11 February 2016). . Springer. pp. 264–265. Hormones and the Endocrine System: Textbook of Endocrinology ISBN . 978-3-319-15060-4
^ a b
Pizzorno JE (2013). . Elsevier Health Sciences. pp. 711–. Textbook of Natural Medicine ISBN . 978-1-4377-2333-5
^ a b
Rainey WE, Nakamura Y (February 2008). "Regulation of the adrenal androgen biosynthesis". The Journal of Steroid Biochemistry and Molecular Biology. 108 (3–5): 281–6. doi: 10.1016/j.jsbmb.2007.09.015. PMC . 2699571 PMID 17945481.
^ a b
Adler RA (14 December 2009). . Springer Science & Business Media. pp. 387–. Osteoporosis: Pathophysiology and Clinical Management ISBN . 978-1-934115-19-0
Schill W, Comhaire FH, Hargreave TB (26 August 2006). . Springer Science & Business Media. pp. 243–. Andrology for the Clinician ISBN . 978-3-540-33713-3
^ a b
Linos DA, van Heerden JA (5 December 2005). . Springer Science & Business Media. pp. 161–. Adrenal Glands: Diagnostic Aspects and Surgical Therapy ISBN . 978-3-540-26861-1
Filaire E, Duché P, Lac G (October 1998). "Effects of amount of training on the saliva concentrations of cortisol, dehydroepiandrosterone and on the dehydroepiandrosterone: cortisol concentration ratio in women over 16 weeks of training". European Journal of Applied Physiology and Occupational Physiology. 78 (5): 466–71. doi: 10.1007/s004210050447. PMID 9809849.
Copeland JL, Consitt LA, Tremblay MS (April 2002). "Hormonal responses to endurance and resistance exercise in females aged 19-69 years". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 57 (4): B158–65. doi: . 10.1093/gerona/57.4.B158 PMID 11909881.
Mattison JA, Lane MA, Roth GS, Ingram DK (2003). "Calorie restriction in rhesus monkeys". Experimental Gerontology. 38 (1–2): 35–46. doi: 10.1016/S0531-5565(02)00146-8. PMID 12543259. .
Roberts E (February 1999). "The importance of being dehydroepiandrosterone sulfate (in the blood of primates): a longer and healthier life?". Biochemical Pharmacology. 57 (4): 329–46. doi: 10.1016/S0006-2952(98)00246-9. PMID 9933021. .
^ a b
Alesci S, Manoli I, Blackman MR (29 December 2004). "Dehydroepiandrosterone (DHEA)". In Coates PM, Blackman MR, Cragg GM, Levine M, Moss J, White JD (eds.). Encyclopedia of Dietary Supplements (Print). CRC Press. pp. 169–. ISBN . 978-0-8247-5504-1
Becker KL (2001). . Lippincott Williams & Wilkins. pp. 712–. Principles and Practice of Endocrinology and Metabolism ISBN . 978-0-7817-1750-2
^ a b
Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA (October 2015). "The Regulation of Steroid Action by Sulfation and Desulfation". Endocr Rev. 36 (5): 526–63. doi: 10.1210/er.2015-1036. PMC . 4591525 PMID 26213785.
Lash LH (2005). . Springer Science & Business Media. pp. 353–. Drug Metabolism and Transport: Molecular Methods and Mechanisms ISBN . 978-1-59259-832-8
Morfin R (2 September 2003). . CRC Press. pp. 28–. DHEA and the Brain ISBN . 978-0-203-30121-0
Karasek M (2006). . Nova Publishers. pp. 66–. Aging and Age-related Diseases: The Basics ISBN . 978-1-59454-426-2
^ a b
White BA, Porterfield SP (2013). . Elsevier Health Sciences. pp. 164–. Endocrine and Reproductive Physiology, Mosby Physiology Monograph Series (with Student Consult Online Access),4: Endocrine and Reproductive Physiology ISBN . 978-0-323-08704-9
Kalimi MY, Regelson W (2000). . Walter de Gruyter. pp. 41–. Dehydroepiandrosterone (DHEA): Biochemical, Physiological and Clinical Aspects ISBN . 978-3-11-016111-3
Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L (2003). "Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia". Roczniki Akademii Medycznej W Bialymstoku. 48: 131–4. PMID 14737959.
^ a b c
Elks J (14 November 2014). . Springer. pp. 641–. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies ISBN . 978-1-4757-2085-3
Edith Josephy; F. Radt (1 December 2013). . Springer. pp. 2608–. Elsevier's Encyclopaedia of Organic Chemistry: Series III: Carboisocyclic Condensed Compounds ISBN . 978-3-662-25863-7
Schwartz AG, Pashko LL (2001). "Potential therapeutic use of dehydroepiandrosterone and structural analogs". Diabetes Technology & Therapeutics. 3 (2): 221–4. doi: 10.1089/152091501300209589. PMID 11478328.
Labrie F, Martel C, Bélanger A, Pelletier G (April 2017). "Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology". The Journal of Steroid Biochemistry and Molecular Biology. 168: 9–18. doi: 10.1016/j.jsbmb.2016.12.007. PMID 28153489.